China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results

Sep 02, 2015, 04:00 ET from China Nepstar Chain Drugstore Ltd.

SHENZHEN, China, Sept. 2, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or the "Company"), a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the second quarter ended June 30, 2015.

Financial Highlights

For the quarter ended June 30, 2015:

  • Revenue increased by 12.9% to RMB775.1 million (US$125.0 million) compared to RMB686.6 million in the second quarter of 2014
  • Same store sales increased by 16.7% compared to the second quarter of 2014
  • Net income was RMB8.7 million (US$1.4 million) compared to a net loss of RMB15.9 million in the second quarter of 2014.

Ms. Rebecca Zhang, Chief Executive Officer, commented: "Our accelerated same-store-sales growth propelled the increase in our revenue. We are encouraged by higher store traffic as a result of our effective promotions on pharmaceutical products and professional store service training. While we focus on productivity at the store level, we also managed to achieve better operational efficiency by reducing our general and administrative expenses and constantly optimizing our store management."

Second Quarter Results

During the second quarter of 2015, the Company opened 38 new stores and closed 59 stores. As of June 30, 2015, the Company had 1,948 directly operated stores in total. 

Revenue for the second quarter of 2015 increased by 12.9% to RMB775.1 million (US$125.0 million) from RMB686.6 million for the same period in 2014. Same store sales (for the 1,768 stores opened before December 31, 2013 and which were still operating as of June 30, 2015) for the second quarter increased by 16.7% compared to the same period in 2014. The increase in same store sales was primarily due to in-store promotional initiatives and marketing of pharmaceutical products.

In the second quarter of 2015, the Company's revenue by product contribution was 23.1% attributable to prescription drugs (23.9% for the same period in 2014), 41.4% attributable to over-the-counter ("OTC") drugs (39.0% for the same period in 2014), 18.7% attributable to convenience and other products (18.8% for the same period in 2014), 12.1% attributable to nutritional supplements (14.8% for the same period in 2014), and 4.7% attributable to herbal products (3.5% for the same period in 2014).

The Company's gross profit increased by 5.7% to RMB309.5 million (US$49.9 million) for the second quarter of 2015 from RMB292.9 million for the same period in 2014. Gross margin in the second quarter of 2015 was 39.9%, compared with 42.7% for the same period in 2014. The year-over-year decrease in gross margin was primarily the result of proactive promotional activities on pharmaceutical products.

The Company's portfolio of private label products included 2,155 types of products as of June 30, 2015. Sales of private label products represented approximately 14.7% of the Company revenue and 22.0% of the gross profit for the second quarter of 2015.

Sales, marketing and other operating expenses as a percentage of revenue decreased to 35.7% for the second quarter of 2015 from 39.0% for the same period in 2014, as the steady growth in revenue outpaced the increases in sales, marketing and other operation expenses.

General and administrative expenses as a percentage of revenue were also reduced to 3.8% for the second quarter of 2015, from 4.6% for the second quarter of 2014. This was primarily due to the improvements in management efficiency.

During the second quarter of 2015, the Company recognized an impairment loss of RMB4.6 million (US$0.7 million), compared to RMB5.2 million for the same period in 2014, representing the reduction of the carrying amount of the property and equipment of certain underperforming stores.

Loss from operations in the second quarter of 2015 was RMB1.6 million (US$0.3 million) compared to loss from operations of RMB11.5 million in the same period of 2014. The loss from operations was mainly due to the lower gross margin.

Interest income for the second quarter of 2015 was RMB1.9 million (US$0.3 million), compared to RMB1.9 million for the same period in 2014.

Dividend income from cost method investments for the second quarter of 2015 was RMB2.9 million (US$0.5 million) compared to RMB 0.9 million for the same period in 2014.

Income before income tax expense for the second quarter of 2015 was RMB3.3 million (US$0.5 million), while we suffered a loss before income tax expense of RMB8.7 million for the same period in 2014.

The Company recorded a net income tax benefit (credit) of RMB5.5 million (US$0.9 million) for the second quarter of 2015, compared to an income tax expense of RMB7.2 million for the same period in 2014. The change included the decreases in the amounts of valuation allowance for certain subsidiaries with improving operating results and certain prior year unrecognized tax benefits being recognized during the current period when the recognition threshold was met..

Net income for the second quarter of 2015 was RMB8.7 million (US$1.4 million), or RMB0.09 (US$0.01) basic and diluted income per ADS, compared to a net loss of RMB15.9 million, or RMB0.16 basic and diluted losses per ADS for the second quarter of 2014. As of June 30, 2015, the Company had 197.4 million outstanding ordinary shares. Each ADS represents two ordinary shares of the Company.

In the second quarter of 2015, net cash inflow from operating activities was RMB12.0 million (US$1.9 million), compared to net cash outflow of RMB79.0 million for the same period in 2014, as a result of our growth in net profit, as well as the utilization of prepayments made to suppliers.

As of June 30, 2015, the Company's total cash, cash equivalents, short-term and long-term bank deposits and restricted cash were RMB349.6 million (US$56.4 million) and its shareholders' equity was RMB836.9 million (US$135.0 million), compared to RMB316.9 million and RMB831.6 million, respectively, as of December 31, 2014.

Business Outlook

"As we gradually achieve recovery in growth on profit, we will focus on accelerating our organic revenue growth by fine-tuning our store management system and improving our store image to customers," Ms. Zhang concluded.

Conference Call Information

The Company will host a conference call, to be simultaneously webcasted, on Wednesday, September 2, 2015 at 8:00 a.m. Eastern Time / 8:00 p.m. Beijing Time. Interested parties may participate in the conference call by dialing +1-877-407-9210 (North America) or +1-201-689-8049 (International) approximately five minutes before the call start time. A live webcast of the conference call will be available on Nepstar's website at www.nepstar.cn.

A replay of the call will be available shortly after the conclusion of the conference call through September 9, 2015 at11:59 p.m. Eastern Time. An archived webcast of the conference call will be available on Nepstar's website at http://www.nepstar.cn. Interested parties may access the replay by dialing +1-877-660-6853 (North America) or +1-201-612-7415 (International) and entering conference ID number 13617349.

About China Nepstar Chain Drugstore Ltd.                                                   

China Nepstar Chain Drugstore Ltd. (NYSE: NPD) is a leading retail drugstore chain in China. As of June 30, 2015, the Company had 1,948 directly operated stores across 72 cities, one headquarter distribution center and 15 regional distribution centers in China. Nepstar uses directly operated stores, centralized procurement and a network of distribution centers to provide its customers with high-quality, professional and convenient pharmaceutical products and services and a wide variety of other merchandise, including OTC drugs, nutritional supplements, herbal products, personal care products, family care products, and convenience products. Nepstar's strategy of centralized procurement, competitive pricing, customer loyalty programs and private label offerings has enabled it to capitalize on the continuing economic growth in China and take advantage of the demographic trend in China to achieve a strong brand and leading market position. For further information, please go to http://www.nepstar.cn.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's strategic operational plans and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Exchange Rate Information

The United States dollar (US$) amounts disclosed in this press release are presented solely for the convenience of the reader. Translations of amounts from RMB into United States dollars were calculated at the certified exchange rate of US$1.00 = RMB6.2000 on June 30, 2015 as set forth in the H.10 weekly statistical release of the Federal Reserve Board. No representation is made that the RMB amounts could have been, or could be, converted into US$ at that rate on June 30, 2015, or at any other date. The percentages stated are calculated based on RMB amounts.

Contacts

Zixin Shao
China Nepstar Chain Drugstore Ltd.
Chief Financial Officer
+86-755-2641-4065
ir@nepstar.cn

(Tables Follow)


China Nepstar Chain Drugstore Ltd.

Unaudited Condensed Consolidated Statements of Comprehensive Income/Loss

(amounts in thousands – except per-share and per-ADS data)




Three-month period ended

June 30,


2014

2015

2015


RMB

RMB

USD





Revenue

686,553

775,083

125,013

Cost of goods sold

(393,606)

(465,627)

(75,101)

Gross profit

292,947

309,456

49,912

Sales, marketing and other operating expenses

(267,539)

(276,719)

(44,632)

General and administrative expenses

(31,703)

(29,741)

(4,797)

Impairment losses of property and equipment

(5,182)

(4,555)

(734)

Loss from operations

(11,477)

(1,559)

(251)

Interest income

1,863

1,944

313

Dividend income from cost method investments

920

2,881

465

(Loss)/income before income tax expense

(8,694)

3,266

527

Income tax expense

(7,201)

5,451

879

Net(loss)/income

(15,895)

8,717

1,406





Basic and diluted(loss)/income per ordinary share

(0.081)

0.044

0.007

Basic and diluted (loss)/income per ADS

(0.162)

0.088

0.014





Net (loss)/income

(15,895)

8,717

1,406





Other comprehensive income/(loss), net of tax:




Foreign currency translation adjustments

25

(13)

(2)

Comprehensive(loss)/income

(15,870)

8,704

1,404

 

China Nepstar Chain Drugstore Ltd.

Unaudited Condensed Consolidated Balance Sheets

(amounts in thousands)








As of


As of


As of

December 31,


June 30,


June 30,


2014


2015


2015


RMB


RMB


USD







ASSETS






Current assets






Cash and cash equivalents

252,174


300,219


48,422

Short-term bank time deposits

24,000


9,000


1,451

Long-term bank time deposits due within one year

3,256


3,256


525

Restricted cash

37,423


37,124


5,988

Accounts receivable, net of allowance for doubtful accounts

136,568


130,087


20,982

Bills receivable

400


122


20

Amounts due from related parties

3,366


4,772


770

Prepaid expenses, deposits and other current assets

245,254


179,284


28,917

Inventories

546,312


577,386


93,127

Deferred tax assets

2,038


4,993


805

Total current assets

1,250,791


1,246,243


201,007







Non-current assets






Property and equipment, net

137,750


145,602


23,484

Rental deposits

42,257


41,916


6,761

Cost method investments

12,638


12,638


2,038

Intangible assets, net

2,509


2,509


405

Goodwill

51,819


51,819


8,358

Deferred tax assets

16,340


15,404


2,484

Other non-current assets

-


35,445


5,717

Total non-current assets

263,313


305,333


49,247

Total assets

1,514,104


1,551,576


250,254







LIABILITIES AND SHAREHOLDERS' EQUITY












Current liabilities






Accounts payable

409,428


451,827


72,875

Amounts due to related parties

25,636


26,217


4,229

Accrued expenses and other payables

122,236


113,565


18,317

Income tax payable

25,743


20,271


3,270

Deferred income

25,715


34,312


5,534

Total current liabilities

608,758


646,192


104,225







Non-current liabilities






Deferred income

15,677


13,253


2,137

Deferred tax liabilities

14,711


15,233


2,457

Other non-current liabilities

43,326


39,949


6,443

Total non-current liabilities

73,714


68,435


11,037

Total liabilities

682,472


714,627


115,262







Shareholders' equity






Share capital

158


158


25

Additional paid-in capital

640,341


640,341


103,281

Accumulated other comprehensive loss

(41,746)


(41,753)


(6,734)

Retained earnings

232,879


238,203


38,420

Total shareholders' equity

831,632


836,949


134,992







Total liabilities and shareholders' equity

1,514,104


1,551,576


250,254

SOURCE China Nepstar Chain Drugstore Ltd.



RELATED LINKS

http://www.nepstar.cn